EasyPGX

EasyPGX® product line - key features 

  • Ready to use: reagents are delivered in 8-well strips preloaded with a complete master mix in a dry, room temperature and stable format
  • Easy to use: no need for freezing, thawing or pipetting on ice and the few remaining pipetting steps minimize the risk of errors or contaminations
  • High sensitivity: limit of detection as low as 0.5%
  • Flexible sample requirement: low DNA input from a variety of sources, including FFPE and plasma
  • Turnaround time: from tissue to result in less than 3 hours with only 10 minutes of hands-on time
  • Quality assurance: manufactured under ISO 13485
  • Regulatory: kits have been designed, developed and validated in accordance with  the Directive 98/79/EC on in vitro diagnostic medical devices

 

From tissue to result in less than 3 hours

EasyPGX® ready KRAS cat. no. RT021 (48 test, CE IVD)

Main features:Detection of the main mutations of exon 2 (codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of the gene KRAS using 8 oligo mixes. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene. A specific oligo control mix enables the evaluation of the quality and the quantity of the DNA in each sample.

EasyPGX® ready BRAF cat. no. RT022 (48 test, CE IVD)

Main features: Detection of the main mutations of codon 600 of the gene BRAF using 4 oligo mixes. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene. A specific oligo control mix enables the evaluation of the quality and the quantity of the DNA in each sample.

EasyPGX® ready EGFR cat. no. RT023 (48 test, CE IVD) 

Main features: Detection of the main mutations of exons 18, 19, 20, 21 of EGFR gene using 8 oligo mixes. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene. A specific oligo control mix enables the evaluation of the quality and the quantity of the DNA in each sample.

EasyPGX® ready NRAS cat. no. RT024 (48 test, CE IVD)

Main features: Detection of the main mutations of exon 2 ( codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of NRAS gene using 8 oligo mixes. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene. A specific oligo control mix enables the evaluation of the quality and the quantity of the DNA in each sample.

EasyPGX® ready DPYD cat. no. RT026 (48 test, CE IVD)

Main features: Detection, by allelic discrimination, of the DPYD gene polymorphisms DPYD*2A (IVS14+1G>A, c.1905+1G>A, rs3918290), DPYD*13 (c.1679T>G, rs55886062), DPYD D949V (c.2846A>T, rs67376798) and DPYD IVS10 (c.1129–5923C>G, rs75017182), associated with the toxicity due to the treatment with Fluoropyrimidines, using 4 oligo mixes. Each mix allows the co-amplification of the mutant sequence (FAM) as well as the wild-type sequence (HEX).

EasyPGX® ready UGT1A1 cat. no. RT027 (48 test, CE IVD)

Main features: Detection, by allelic discrimination, of the UGT1A1 gene polymorphisms UGT1A1*1 (TA)6, UGT1A1*28 (TA)7, UGT1A1*36 (TA)5 and UGT1A1*37 (TA)8, associated with the toxicity due to the treatment with Irinotecan, using 1 oligo mix. UGT1A1 mix contains HEX labeled probes for UGT1A1*28 and UGT1A1*37 and FAM labeled probes for UGT1A1*1 UGT1A1*37 and FAM labeled probes for UGT1A1*1

EasyPGX® ready Thyroid cat. no. RT028 (48 test, CE IVD)

Main features: Detection of the main mutations of exon 2 (codons 12,13), of exon 3 (codons 61) of the genes KRAS, NRAS, HRAS and of the codons 600 and 601 of the gene BRAF using 8 oligo mixes. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene.

Helix® circulating Nucleic Acid cat. no. H8040 (50 test, CE IVD) 

The kit allows the manual extraction of circulating free DNA (cfDNA) from plasma. The kit Helix® Circulating Nucleic Acid, in association with the kit EasyPGX® ready EGFR, enables the mutational analysis of EGFR gene in the circulating tumor DNA (liquid biopsy) when the tumor tissue is not evaluable, according to the EMA/129677/2014 recommendations of September 25th 2014.
Main features: DNA capture by silica membrane and vacuum-based system. The system to concentrate the final eluate up to 3 times is included in the kit.


DOWNLOAD


  • easyPGX Ready to yoUSE